Shots:
- Rznomics has signed a strategic global license agreement with Eli Lillyto develop & commercialize RNA-editing therapies for inherited hearing loss using Rznomics’ trans-splicing ribozyme platform
- As per the deal, if Lilly avail all its options then total deal value could surpass $1.3B with undisclosed upfront payment, in addition to separate royalties from product sales
- The partnership targets RNA-editing therapies for sensorineural hearing loss, with Rznomics leading early research and Lilly handling later development and commercialization
Ref: PRNewswire | Image: Rznomics and Eli Lilly | Press Release
Related News:- Eli Lilly Enters a ~$415M Licensing Agreement with Alchemab Therapeutics for ATLX-1282 to Treat Amyotrophic Lateral Sclerosis (ALS)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
